{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:11:35Z","timestamp":1778703095956,"version":"3.51.4"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jns.2026.125963","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:31:22Z","timestamp":1777332682000},"page":"125963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Methodological considerations in evaluating lifetime estrogen exposure and neurodegeneration in multiple sclerosis"],"prefix":"10.1016","volume":"486","author":[{"given":"Arif","family":"Sahin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ismah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Ayu","family":"Herawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muh. Azhar","family":"Mubarak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia Rizki","family":"Pautina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"February","key":"10.1016\/j.jns.2026.125963_bb0005","article-title":"A proof-of-concept study on the relationship between lifetime estrogen exposure, menopausal transition, and neurodegeneration in women with multiple sclerosis","volume":"484","author":"Ianniello","year":"2026","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2026.125963_bb0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/IJPSYM.IJPSYM_504_19","article-title":"Sample size and its importance in research","volume":"42","author":"Andrade","year":"2020","journal-title":"Indian J. Psychol. Med."},{"issue":"02","key":"10.1016\/j.jns.2026.125963_bb0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0040-1722104","article-title":"Sample size calculation in medical research: a primer","volume":"57","author":"Charan","year":"2021","journal-title":"Annals of the National Academy of Medical Sciences (India)"},{"issue":"1","key":"10.1016\/j.jns.2026.125963_bb0020","article-title":"The importance of sample size in research studies","volume":"7","author":"Mishra","year":"2021","journal-title":"Med. Econ."},{"key":"10.1016\/j.jns.2026.125963_bb0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4103\/endo.endo_235_23","article-title":"Sample size considerations in research","volume":"35","author":"Sivasamy","year":"2023","journal-title":"Endodontology (New Delhi)"},{"issue":"11","key":"10.1016\/j.jns.2026.125963_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/psyp.13437","article-title":"Methodological reporting behavior, sample sizes, and statistical power in studies of event-related potentials: barriers to reproducibility and replicability","volume":"56","author":"Clayson","year":"2019","journal-title":"Psychophysiology"},{"issue":"4","key":"10.1016\/j.jns.2026.125963_bb0035","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0017-22.2022","article-title":"Questionable research practices, low statistical power, and other obstacles to replicability: why preclinical neuroscience research would benefit from registered reports","volume":"9","author":"Ellis","year":"2022","journal-title":"eNeuro"},{"issue":"3","key":"10.1016\/j.jns.2026.125963_bb0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.biopsych.2015.06.016","article-title":"Statistical and methodological considerations for the interpretation of intranasal oxytocin studies","volume":"79","author":"Walum","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2026.125963_bb0045","series-title":"Controlling the Risk of False Positive Clinical Trials","first-page":"103","author":"Cleophas","year":"2012"},{"issue":"14","key":"10.1016\/j.jns.2026.125963_bb0050","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jama.2017.13276","article-title":"Gatekeeping strategies for avoiding false-positive results in clinical trials with many comparisons","volume":"318","author":"Yadav","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jns.2026.125963_bb0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1874297101003010016","article-title":"Power and error: increased risk of false positive results in underpowered studies","volume":"3","author":"Christley","year":"2010","journal-title":"Open Epidemiol. J."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:06:39Z","timestamp":1778702799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26002455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":11,"alternative-id":["S0022510X26002455"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125963","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methodological considerations in evaluating lifetime estrogen exposure and neurodegeneration in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125963"}}